Preemptive Rituximab for Epstein-Barr Virus Reactivation after Hematopoietic Cell Transplantation: Necessary for All?
{{output}}
Introduction: In allogeneic HCT recipients, risk factors for PTLD and EBV end-organ diseases are well established. Therefore, weekly monitoring of EBV reactivation with quantitative PCR is indicated for patients at risk. Although... ...
